Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Limited : Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 08:21pm CEST

IRVINE, CA / ACCESSWIRE / October 4, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors, who purchased or otherwise acquired shares from November 15, 2016 through August 2, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
05:35a TEVA PHARMACEUTICAL INDUSTRIES LIMIT : 3-DAY DEADLINE: Khang & Khang LLP Announc..
10/20 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Levi & Korsinsky, LLP Re..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Lundin Law PC Announces ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Report Third Quarter 2017 Financial Results ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : The Law Offices of Vincent Wong Reminds I..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Highlight New Data in Multiple Sclerosis at ..
10/18 TEVA REMINDER DEADLINE ALERT : The Law Offices of Howard G. Smith Reminds Invest..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : APPROACHING DEADLINE: Khang & Khang LLP A..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Levi & Korsinsky, LLP Reminds Shareholder..
More news
News from SeekingAlpha
10/20 Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 J&J : Unattractive
10/18 TEVA BULLS ARE TOO EARLY : Debt Downgrade On The Way
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,17x
EV / Sales 2018 2,06x
Capitalization 14 797 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 92%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-62.38%14 797
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223